Clinical Trials Logo

Clinical Trial Summary

B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily will be evaluated relative to placebo over 12 weeks. The efficacy of the two dosage strengths of PF-04965842 will be compared with dupilumab in terms of pruritus relief at 2 weeks. The two dosage strengths of PF-04965842 and dupilumab 300 mg injected subcutaneously once every two weeks (with a loading dose of 600 mg injected on the first day) will also be evaluated relative to placebo over 16 weeks. The safety of the investigational products will be evaluated over the duration of the study. Subjects will use non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study. Subjects who are randomized to receive one of the two dosage strengths of PF-04965842 will also receive placebo injectable study drug every two weeks until Week 16 and then will continue on receiving only the oral study drug for 4 weeks. Subjects who are randomized to receive dupilumab injections every two weeks will also receive oral placebo to be taken once daily until Week 16 and will then continue to receive only the oral placebo for 4 weeks. Subjects who are randomized to the placebo arms, will receive both daily oral placebo and injectable placebo every two weeks until Week 16, after which they will receive either 100 mg or 200 mg of PF-04965842 taken orally once daily for 4 weeks, dependent upon which arm they have been allocated to. Eligible subjects will have an option to enter a long-term extension study after completing 20 weeks of treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03720470
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date October 29, 2018
Completion date March 6, 2020

See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Terminated NCT04086121 - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 Phase 2
Recruiting NCT04011215 - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2) N/A
Completed NCT04635072 - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis Early Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT01945086 - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis Phase 2
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Terminated NCT04990440 - A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT02900131 - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients Phase 2
Completed NCT03568136 - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Phase 2
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03672383 - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation) N/A
Completed NCT03634345 - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. Phase 1
Enrolling by invitation NCT04761978 - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed NCT03663673 - Effect of Different Skin Creams on TEWL Phase 1
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT02637206 - Skin Irritation Study of GSK2894512 Cream Phase 1
Completed NCT05544591 - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05094700 - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants N/A
Terminated NCT02582788 - Bathing Additives in Pediatric Atopic Dermatitis N/A